These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37096066)

  • 1. Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway.
    Zhang Z; Zhang D; Wang F; Liu J; Sun Y; Anuchapreeda S; Tima S; Xiao Z; Duangmano S
    PeerJ; 2023; 11():e15172. PubMed ID: 37096066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sema4D/Plexin-B1 promotes the progression of osteosarcoma cells by activating Pyk2-PI3K-AKT pathway.
    Li C; Wan L; Wang P; Guan X; Li C; Wang X
    J Musculoskelet Neuronal Interact; 2021 Dec; 21(4):577-583. PubMed ID: 34854398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
    Cao J; Zhang C; Chen T; Tian R; Sun S; Yu X; Xiao C; Wang G; Liu Y; Fu M; Li W
    J Dermatol Sci; 2015 Aug; 79(2):127-36. PubMed ID: 26051877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways.
    Jiang H; Tang J; Qiu L; Zhang Z; Shi S; Xue L; Kui L; Huang T; Nan W; Zhou B; Zhao C; Yu M; Sun Q
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling.
    Liu L; Yang L; Liu X; Liu M; Liu J; Feng X; Nie Z; Luo J
    J Transl Med; 2022 Jul; 20(1):304. PubMed ID: 35794581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plexin-B1 activates NF-κB and IL-8 to promote a pro-angiogenic response in endothelial cells.
    Yang YH; Zhou H; Binmadi NO; Proia P; Basile JR
    PLoS One; 2011; 6(10):e25826. PubMed ID: 22028792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of SEMA4D in recurrent implantation failure induces reduction of trophoblast invasion and migration via the Met/PI3K/Akt pathway.
    Chen X; Qi L; Zhao C; Xue J; Chen M; Diao L; He W; Lv B; Zeng Y; Xue Z
    J Reprod Immunol; 2022 Sep; 153():103657. PubMed ID: 35816784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo anti-malignant melanoma activity of Alocasia cucullata via modulation of the phosphatase and tensin homolog/phosphoinositide 3-kinase/AKT pathway.
    Fang M; Zhu D; Luo C; Li C; Zhu C; Ou J; Li H; Zhou Y; Huo C; Liu W; Peng J; Peng Q; Mo Z
    J Ethnopharmacol; 2018 Mar; 213():359-365. PubMed ID: 29180042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth.
    Soong J; Chen Y; Shustef EM; Scott GA
    J Invest Dermatol; 2012 Apr; 132(4):1230-8. PubMed ID: 22189792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells.
    Kou Y; Li L; Li H; Tan Y; Li B; Wang K; Du B
    Biochem Biophys Res Commun; 2016 Oct; 479(2):290-296. PubMed ID: 27639645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes.
    Soong J; Scott G
    J Cell Sci; 2013 Jan; 126(Pt 2):688-95. PubMed ID: 23203808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition.
    Sun Z; Zheng L; Liu X; Xing W; Liu X
    Drug Des Devel Ther; 2018; 12():2413-2421. PubMed ID: 30122899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
    Li CY; Wang Q; Wang XM; Li GX; Shen S; Wei XL
    Eur J Pharmacol; 2019 Dec; 864():172719. PubMed ID: 31586634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF‑κB and PI3K/Akt signaling pathways.
    Liao Z; Zhao J; Yang Y
    Mol Med Rep; 2018 May; 17(5):7313-7318. PubMed ID: 29568965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. circ_NRIP1 is oncogenic in malignant development of esophageal squamous cell carcinoma (ESCC) via miR-595/SEMA4D axis and PI3K/AKT pathway.
    Zhou S; Guo Z; Zhou C; Zhang Y; Wang S
    Cancer Cell Int; 2021 May; 21(1):250. PubMed ID: 33957921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway.
    Shin DH; Kim OH; Jun HS; Kang MK
    Exp Mol Med; 2008 Oct; 40(5):486-94. PubMed ID: 18985006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3-induced upregulation of lncRNA SNHG17 predicts a poor prognosis of melanoma and promotes cell proliferation and metastasis through regulating PI3K-AKT pathway.
    Gao H; Liu R; Sun X
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8000-8010. PubMed ID: 31599425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
    Li CY; Wang Q; Wang X; Li G; Shen S; Wei X
    Eur J Pharmacol; 2019 Sep; 858():172463. PubMed ID: 31211986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis.
    Okuno T; Nakatsuji Y; Moriya M; Takamatsu H; Nojima S; Takegahara N; Toyofuku T; Nakagawa Y; Kang S; Friedel RH; Sakoda S; Kikutani H; Kumanogoh A
    J Immunol; 2010 Feb; 184(3):1499-506. PubMed ID: 20038643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.